tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Outlook for ARS Pharmaceuticals: Buy Rating Affirmed by Lachlan Hanbury Brown
PremiumRatingsPromising Outlook for ARS Pharmaceuticals: Buy Rating Affirmed by Lachlan Hanbury Brown
19d ago
ARS Pharmaceuticals Reports Q3 2025 Financial Results
Premium
Company Announcements
ARS Pharmaceuticals Reports Q3 2025 Financial Results
19d ago
ARS Pharmaceuticals reports Q3 EPS (52c), consensus (49c)
Premium
The Fly
ARS Pharmaceuticals reports Q3 EPS (52c), consensus (49c)
19d ago
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
PremiumCompany AnnouncementsArs Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
1M ago
Ars Pharmaceuticals’ Promising Study on ARS-2 for Chronic Urticaria: What Investors Need to Know
Premium
Company Announcements
Ars Pharmaceuticals’ Promising Study on ARS-2 for Chronic Urticaria: What Investors Need to Know
1M ago
ARS Pharmaceuticals receives favorable decision from EPO on neffy
Premium
The Fly
ARS Pharmaceuticals receives favorable decision from EPO on neffy
2M ago
3 Best Stocks to Buy Now, 9/23/2025, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Now, 9/23/2025, According to Top Analysts
2M ago
Global Expansion and Strategic Advancements Drive Buy Rating for ARS Pharmaceuticals
Premium
Ratings
Global Expansion and Strategic Advancements Drive Buy Rating for ARS Pharmaceuticals
2M ago
ARS Pharmaceuticals announces neffy approved in Japan
Premium
The Fly
ARS Pharmaceuticals announces neffy approved in Japan
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100